Podcasts about healthcare markets

The data doesn't lie: site-of-care shifts are accelerating. Health systems rely on surgical volumes as a major revenue driver, but as more procedures take place outside of the hospital, systems are not necessarily positioned to capture the shift in volumes – or revenues. So, what should health systems do? To answer that question, host Abby Burns talks with Advisory Board experts Nick Hula and Sebastian Beckmann. They discuss why health systems need to transition from a "defensive" to "offensive" approach to capture shifting volumes and identify service- and market-level factors systems should consider when putting this mindset shift into action. Links: Site-of-care shifts: The next savings opportunity for health plans? Ep. 193: Is health system growth still possible? 5 trends (re)shaping site-of-care shifts What's happening with joint replacement volumes? Learn more about Advisory Board's on-demand courses Learn more about the Advisory Board Fellowship at: advisory.com/fellowship A transcript of this episode as well as more information and resources can be found on radioadvisory.advisory.com.

In this ATP episode Bhargavi Battala  & Sowmya Prabhakar discuss the finer details of how smart nudges such as display boards in the park, mobile vans in remote areas, reminder messages on birthday's & badges have a role to play in preventive care. We also talk about the role of the Australian Government & the markets which make the breast screening process feasible.Do check out Takshashila's public policy courses: https://school.takshashila.org.in/courses We are @‌IVMPodcasts on Facebook, Twitter, & Instagram. https://twitter.com/IVMPodcasts https://www.instagram.com/ivmpodcasts/?hl=en https://www.facebook.com/ivmpodcasts/ You can check out our website at https://shows.ivmpodcasts.com/featured Follow the show across platforms: Spotify, Google Podcasts, Apple Podcasts, JioSaavn, Gaana, Amazon Music Do share the word with your folksSee omnystudio.com/listener for privacy information.

Can the Government Make Healthcare Markets More Competitive? David Johnson and Julie Murchinson discuss whether the federal government can make healthcare market more competitive through regulation on the new episode of the 4sight Health Roundup podcast moderated by David Burda. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/

David W. Johnson and Julie Murchinson discuss whether the federal government can make healthcare more competitive through regulation. Do you think it's possible? The discussion, “Can the Government Make Healthcare Markets More Competitive?” is all there in the new episode of the 4sight Health Roundup podcast moderated by David Burda.

Understanding healthcare spending growth in America is a critical component of any initiative attempting to improve care quality and affordability. This holds true for every person or organization focused on improving healthcare – from policy makers, to traditional healthcare incumbents, new entrants, and the entrepreneurs driving digital health innovation.There are few people who understand healthcare economics in the U.S. as well as Michael Chernew, PhD, who has dedicated his career to studying healthcare spending and how it affects the quality of care and outcomes. Dr. Chernew is the Leonard D. Schaeffer Professor of Health Care Policy, and director of the Healthcare Markets and Regulation Lab in the Department of Health Care Policy at Harvard Medical School. Among many other roles, he is also currently serving as the Chair of the Medicare Payment Advisory Commission (MedPAC), an independent agency that advises Congress on costs, payments and other issues affecting the Medicare program.Dr. Chernew's research examines several areas related to improving the health care system including studies of novel benefit designs, Medicare Advantage, alternative payment models, low value care and the causes and consequences of rising health care spending.In this episode of Healthcare is Hard, Dr. Chernew shares his knowledge with Keith Figlioli in a discussion that touches a broad range of topics around healthcare economics and innovation, including:The false choice between free markets and government intervention. While some people argue for a stronger government role in healthcare, others believe there needs to be better mechanisms to make markets work better. Dr. Chernew says we need to use the power of the markets where we can and sees a lot of potential for innovation to play a role. But he is also skeptical about how much markets can accomplish on their own. He says the most important thing is to recognize that both the government and the markets are flawed, and he talks about the need to understand where flaws exist in order to navigate them.The appetite for disruptive innovation. There are a lot of organizations now that believe they can deliver good population health for less and capture the gains associated with that efficiency. While the effectiveness of these new approaches generally remains to be seen, Dr. Chernew talks about how there are now many mechanisms in place that will allow organizations to accept risk, along with an appetite for innovation that has grown exponentially over the last decade – especially if it can lower spending.Skepticism on the impact of better primary care. There's a common belief that more and better primary care will ultimately save money because everyone would be healthier. This might be true in some places or situations, but Dr. Chernew says he's very skeptical of the assertion that it could scale in the current system. He explains how saving money is typically achieved by eliminating low value care and providing high value care more efficiently, and talks about potential alternatives for expanding primary care as it exists today.The high cost of drugs. There's a lot of disfunction in the drug market in terms of pricing and value, and the way Dr. Chernew explains it, high costs are really financing future innovation. He says there are core debates about how much innovation should be financed, and how much innovation will occur as a result. He talks about options for designing potential structural changes and incentives to address these issues.To hear Keith and Dr. Chernew talk about these topics and more, listen to this episode of Healthcare is Hard: A Podcast for Insiders.

In this episode we are diving into the topic of healthcare markets together with Simon Reif. He explains to us what makes the healthcare market so special, why its characteristics call for regulation and how systems differ substantially across countries. Focusing on Europe we discuss how, counterintuitively, setting a "global budget" for hospitals leads to poorer service and how generating the right incentives could change the healthcare market for the better in future.   Simon Reif is a health economist heading the research group “Health Markets and Health Policy” at the Leibniz Centre for European Economic Research (ZEW) in Mannheim, Germany. His research is focused on market structures, reimbursement and digitalization of health care provision.

In this third installment of Ropes & Gray's podcast series exploring regulatory and antitrust issues for healthcare industry participants, healthcare partner Stephanie Webster and litigation & enforcement partner Jane Willis discuss the U.S. Department of Justice's (“DOJ”) recent withdrawal of three healthcare enforcement policy statements and its implications for hospital systems, physician practices, and private equity-backed healthcare firms. 

There are many considerations for independent publishers wanting to sell books in the government, education, and healthcare markets. How is selling into these markets different from the retail trade? How do you get started? What are some reasons independent publishers may or may not want to pursue these markets? What are some tips for doing this well? IBPA Board Chair Karen Pavlicin, publisher of Elva Resa Publishing and owner of Military Family Books, shares tips and insights from her 25+ years of navigating bulk sales, niche markets, and community advocacy programs as a primary business model.PARTICIPANTSKaren Pavlicin is the founder and publisher at Elva Resa Publishing, a traditional publisher specializing in resources for and about military families. She also owns and operates Military Family Books, an independent bookstore and wholesale distributor specializing in bulk sales to the military, education, and healthcare markets. She served four years on the IBPA Board of Directors and is the current board chair.Independent Book Publishers Association is the largest trade association for independent publishers in the United States. As the IBPA Director of Membership & Member Services, Christopher Locke helps guide the 4,100+ members as they travel along their publishing journeys. As one of his major projects, he oversees the IBPA NetGalley program, which generates buzz and garners reviews for indie publishers' titles. He's also passionate about indie publishing, because he's an author publisher himself, having published two novels so far in his YA trilogy, The Enlightenment Adventures.LINKSTo learn more about the many benefits of becoming a member of Independent Book Publishers Association, visit here https://www.ibpa-online.org/general/register_member_type.asp?Follow IBPA on:Facebook – https://www.facebook.com/IBPAonlineTwitter – https://twitter.com/ibpaInstagram - https://www.instagram.com/ibpalovesindies/Follow Elva Rese Publishing on:Websites: ElvaResa.com, MilitaryFamilyBooks.comSocial accounts:Facebook: @ElvaResaPublishing @KarenPavlicin @MilitaryFamilyBooks.comhttps://fb.com/ElvaResaPublishinghttps://fb.com/KarenPavlicin (public page)https://fb.com/MilitaryFamilyBooksTwitter: @ElvaResa @Pavlicin @MilFamBookshttps://twitter.com/ElvaResahttps://twitter.com/pavlicinhttps://twitter.com/MilFamBooksIG: @ElvaResaPublishing @KarenPavlicin @MilitaryFamilyBookshttps://instagram.com/ElvaResaPublishinghttps://instagram.com/KarenPavlicinhttps://instagram.com/MilitaryFamilyBooksLI: @ElvaResaPublishing, @Pavlicinhttps://www.linkedin.com/company/elvaresapublishing/https://www.linkedin.com/in/pavlicin/YouTube: @ElvaResahttps://www.youtube.com/user/elvaresa

Join Health Affairs Insider.This week on Health Affairs Forefront (formerly known as the Health Affairs Blog), Michael Chernew, director of the Healthcare Markets and Regulation Lab in the Department of Health Care Policy at Harvard Medical School, and Michael McWilliams, professor of medicine at Harvard Medical School, wrote a piece making the case for accountable care organizations (ACOs) and how fee-for-service payment models lack efficiency.Today on Health Affairs This Week, Michael Chernew joins Health Affairs Forefront Editor Chris Fleming to discuss the Forefront piece, ACOs, direct contracting, why health care payment reform remains necessary in 2022, and more.Related Links: The Case For ACOs: Why Payment Reform Remains Necessary (Health Affairs Forefront) Medicare Advantage, Director Contracting, And The Medicare 'Money Machine," Part 1: The Risk-Score Game (Health Affairs Forefront) Coding-Driven Changes In Measured Risk In Accountable Care Organizations (Health Affairs) Podcast: Matthew Trombley on Why Many Providers Run From Downside Risk In ACOs (A Health Podyssey) Subscribe: RSS | Apple Podcasts | Spotify | Castro | Stitcher | Deezer | Overcast

Tune into this episode of PwC's Next in Health to hear Strategy& Principal, Igor Belokrinitsky and PwC's Health Industries Vice Chair, Jenny Colapietro, in discussion with PwC Director, James Lin, on price transparency regulations , including:Key implications and considerations for payers, providers and pharma and life sciencesImpacts to consumer behavior and market pricingHow to improve the relationship between price and quality transparency

Episode 17 has arrived! Anshita Rai, the Director of Healthcare Markets for Commercial Financial Services at the Royal Bank of Canada, joins us on this episode to discuss her career journey from biotechnology innovation research into the exciting world of commercial banking. Anshita provided some fantastic insights on the skillsets that translate from science to business, how banking services play a critical role in clinical success, and what innovations are coming to commercial banking in healthcare in the future. Abhinav then finishes off the episode by providing some info on starting a career in investment banking in healthcare. Thank you to Anshita for joining us and to all of our listeners for following along! --- Send in a voice message: https://anchor.fm/healthcarehubpodcast/message

President Biden's latest executive order seeks to make the hospital, health insurance and prescription markets more competitive and more affordable for consumers. Will it work? We talked about it on today's episode of the 4sight Friday Roundup podcast. Here the week's biggest news around market-based change. David Johnson is CEO of 4sight Health. Julie Vaughan Murchinson is Partner of Transformation Capital and former CEO of Health Evolution. David Burda is News Editor and Columnist of 4sight Health. Subscribe on iTunes, Spotify, other services. Click play to listen to the 7/16/2021 Episode.

Making Healthcare Markets More Competative This week host David Burda with his panel, Julie Murchinson and David Johnson highlight President Biden's latest executive order seeks to make the hospital, health insurance and prescription markets more competitive and more affordable for consumers. Will it work? Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/

The number of uninsured Americans has grown because of job losses due to COVID-19. Today's resource will help the uninsured acquire health insurance. Our Website: http://our-pac.com Legal: https://www.our-pac.com/about.html Join Our Mailing List: https://bit.ly/3hxxRxQ --- Send in a voice message: https://anchor.fm/ourunitedresourcepac/message

Dr. Charles Kennedy, CEO of Blue Ox Healthcare Partners, discusses updates in treatments and vaccines for Covid-19.

Dr. Michael Chernew is a professor of health care policy and the director of the Healthcare Markets and Regulation Lab at Harvard Medical School. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. M.E. Chernew. The Role of Market Forces in U.S. Health Care. N Engl J Med 2020;383:1401-1404.

Host Matt Fisher chats with Marty Callahan, President of Healthcare Markets at RevSpring. Shifting financial responsibility and burden on patients; engaging patients to develop opportunities for revenue enhancement; role of social determinants in delivery of care and ability to collect; availability of information to drive competition are the topics they tackle. Want to stream our station live? Visit www.HealthcareNOWRadio.com. Find all of our show podcasts on your favorite podcast channel and of course on Apple Podcasts in your iTunes store or here: https://podcasts.apple.com/us/podcast/healthcarenow-radio/id1301407966?mt=2

Listen NowIn CMS' proposed hospital outpatient rule published in the Federal Register in early August, the agency proposed requiring hospitals to make public a list of its negotiated rates for common items and services.   The proposed rule is based on two White House executive orders and is an expansion of a related regulatory rule that went into effect this past January 1st that requires hospitals to make publicly available a list of current standard hospital charges (on their so called chargemaster list).  Despite the administration's enthusiasm for price transparency (and state's - approximately half have passed price transparency legislation) the evidence to date demonstrates that price transparency has not led to or enabled patients to lower their out of pocket costs, lower health care prices, improve market competition creating greater care value.   During this 24 minute conversation Professor Michael Chernew begins by discussing related anti-trust enforcement.  He moreover discusses his research findings concerning price transparency, alternative practices providers have or can exhibit that have demonstrated success in lowering patient out of pocket spending and potential unintended negative consequences, e.g., hospitals may demonstrate less willingness to make price concessions for fear of having to extent them to all payers, should CMS' rule go final as proposed in November. Professor Michael Chernew is the Leonard D. Schaeffer Professor of Health Care Policy and the director of the Healthcare Markets and Regulation (HMR) Lab in the Department of Health Care Policy at Harvard Medical School.  Professor Chernew is a member of the Congressional Budget Office's Panel of Health Advisors and of the Institute of Medicine's Committee on National Statistics (CNSTAT).  He is also a research associate at the National Bureau of Economic Research.  In 2011, he served on the Institute of Medicine's Committee on Determination of Essential Health Benefits and in 2010 was elected to the Institute of Medicine of the National Academy of Sciences.  Prof. Chernew is the former Vice Chair of the Medicare Payment Advisory Commission (MedPAC).  In April 2015, Massachusetts Governor Charlie Baker appointed Professor Chernew to the Massachusetts Health Connector Board of Directors.  Dr. Chernew is currently a co-editor of the American Journal of Managed Care and editor of the Journal of Health Economics.  He is a former senior associate editor of Health Services Research.  Professor Chernew earned his undergraduate degree from the University of Pennsylvania and his PhD in economics from Stanford University.The two White House Executive Orders noted are at: https://www.whitehouse.gov/presidential-actions/executive-order-improving-price-quality-transparency-american-healthcare-put-patients-first/ and at: https://www.whitehouse.gov/presidential-actions/presidential-executive-order-promoting-healthcare-choice-competition-across-united-states/ The White House's related, "Reforming America's Health System" paper is at: https://www.hhs.gov/sites/default/files/Reforming-Americas-Healthcare-System-Through-Choice-and-Competition.pdfCMS' current proposed rule discussing expanding hospital price transparency regulations is at: https://www.govinfo.gov/content/pkg/FR-2019-08-09/pdf/2019-16107.pdf . See pages 39571, ff. The summary of Prof. Chernew, et al. April 2018 New England Journal of Medicine price transparency research article noted during this podcast is at: https://newsatjama.jama.com/2019/08/22/jama-forum-price-transparency-in-health-care-has-been-disappointing-but-it-doesnt-have-to-be/  This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.thehealthcarepolicypodcast.com

Dave Terry, CEO of Boston-based Archway Health, joins host Dr. Bob Kaiser, director of the master's degree program in healthcare leadership and management for professionals at the Naveen Jindal School of Management. They discuss how healthcare payment reforms such as the bundled payment initiatives found in Medicare can fit into the commercial healthcare market to drive down costs while improving patient outcomes. Archway Health recently published a white paper in partnership with the Health Care Transformation Taskforce that explains the 10 elements essential to a bundled payment contract.    

As 2018 draws to a close, The American Journal of Managed Care® (AJMC®)'s co-editors-in-chief, A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design at the University of Michigan, and Michael E. Chernew, PhD, director of the Healthcare Markets and Regulation Lab at Harvard Medical School, recapped their favorite AJMC® papers published in 2018, identified events from the year that are likely to impact future research in the journal, and looked ahead to 2019 with healthcare and health policy predictions. Read more about the papers and news events mentioned: Financial Burden of Healthcare Utilization in Consumer-Directed Health Plans: https://www.ajmc.com/journals/issue/2018/2018-vol24-n4/financial-burden-of-healthcare-utilization-in-consumer-directed-health-plans A Randomized, Pragmatic, Pharmacist-Led Intervention Reduced Opioids Following Orthopedic Surgery: https://www.ajmc.com/journals/issue/2018/2018-vol24-n11/a-randomized-pragmatic-pharmacistled-intervention-reduced-opioids-following-orthopedic-surgery Overall US Healthcare Spending Growth Slowed for Second Year, CMS Says: https://www.ajmc.com/focus-of-the-week/overall-us-healthcare-spending-growth-slows-for-second-year-cms-says Levers to Reduce Use of Unnecessary Services: Creating Needed Headroom to Enhance Spending on Evidence-Based Care: https://www.ajmc.com/journals/issue/2018/2018-vol24-n8/levers-to-reduce-use-of-unnecessary-services-creating-needed-headroom-to-enhance-spending-on-evidencebased-care Addressing Low-Value Care and a Better Benefit Design at the V-BID Summit: https://www.ajmc.com/managed-care-cast/addressing-lowvalue-care-and-a-better-benefit-design-at-the-vbid-summit Federal Judge Strikes Down Affordable Care Act: https://www.ajmc.com/newsroom/federal-judge-strikes-down-affordable-care-act In the Wake of ACA Ruling, the Only Thing Certain Is Uncertainty: https://www.ajmc.com/focus-of-the-week/in-the-wake-of-aca-ruling-the-only-thing-certain-is-uncertainty

Liza Goodspeed is an Analyst at Accenture Strategy with a strong interest in the healthcare industry. During her time at Accenture (she started in August 2017) Liza has assessed the current state of a call center and assisted with designing a transformation strategy through agent observations, stakeholder interviews and analysis of call patterns, call types and FTE data.  The findings were then translated into several business cases with corresponding implementation charters and an integrated roadmap. Liza has also worked on things like patient access and revenue cycle transformation and clinical variation reduction strategies. She didn’t get interested in this field, until her senior year at the University of Pennsylvania, where she’d been pre-med and expected to go into medical school, not into the business world.  Liza graduated from U Penn in 2017 with a bachelor’s degree in Health and Societies and Healthcare Markets and Financing. The post 87: What an Analyst Does At Accenture Strategy w/ Liza Goodspeed, Accenture Strategy [Main T4C episode] appeared first on Time4Coffee.

This episode is going to explain my analysis on the Biotechnology, and Healthcare Markets, and is going to explain what you should do in this market correction.

Prof. Chatterjee shares some of his on-going work on the incentives for innovation in Indian vaccine markets in the face of health shocks like influenza pandemics and the role of disempowerment in deepening the choice of pharmaceutical. He speaks about issues like 1) the welfare effects of hospital consolidation in India 2) the productivity effects of adoption of artificial intelligence and technology like electronic health records in Indian healthcare organizations and 3) adverse health outcome consequences potentially from a price control regime in medical stents. In conclusion, he outlines the pivotal role of data, evidence and policy in guiding optimal regulation to facilitate access and innovation in healthcare markets around the world and especially in transforming economies like India.

Mark Tomaino is an Operating Partner at Welsh, Carson, Anderson & Stowe, a New York City based private equity firm that invests, principally, in two markets, healthcare and information/business services. Mark's focus is exclusively on healthcare technology investment opportunities, including deal generation, due diligence, execution and portfolio company monitoring.   Mark has served on the board of directors of Matrix Medical Network and GetWellNetwork. Prior to September 2010, Mark served as Senior Vice President, Corporate Development and M&A at The TriZetto Group, a leading healthcare information technology company to the healthcare payer industry, where he had responsibility for developing and executing its external growth strategies, including mergers and acquisitions, strategic alliances, joint ventures, investments and capital raising activities. Mark initiated the $1.4 billion go-private transaction with Apax Partners in August 2008 ending TriZetto's tenure as a NASDAQ-listed public company. Prior to joining TriZetto, Mark worked at Bausch & Lomb Incorporated in a variety of legal, strategy and business development capacities. Mark holds an M.B.A. from The Paul Merage School of Business, University of California, Irvine, where he was Valedictorian and a member of the Beta Gamma Sigma Society, a J.D. from the Albany Law School of Union University, where he was a member of the Law Review, and an A.B. in English and Economics from the College of the Holy Cross. 0:00 The inside scoop of the J.P. Morgan Conference. 01:30 “What does Trump mean to the Healthcare Markets, and Investment Opportunities?” 02:00 “Where there's uncertainty, there's risk and volatility.” 03:15 Risk-Adjusted Rates of Return. 04:00 The risk-free aspects of Healthcare. 04:20 The High-risk aspects of Healthcare right now. 05:25 “Ultimately more competition means lower pricing.” 08:00 Investments and Episodic Care Claims. 10:20 Relying on the skills of a Venture Capitalist. 11:00 Looking at Demand-Drivers. 13:15 “The reality is we all are going to be paying more for healthcare in the future.” 13:30 Thinking about the actual Value Proposition to the consumer. 15:00 Who Innovation is targeted to. 16:20 Patient Acquisition, Patient Satisfaction, Patient Engagement. 16:50 New Innovations in Patient Engagement that Mark finds intriguing. 20:00 Looking at Care Coordination Technologies. 21:00 Connecting the Mission of Healthcare with the Business of Healthcare. 21: 15 Patient Experience as the Evaluation of Healthcare Business. 22:00 Navigating the many types of Healthcare Innovation Technologies. 22:30 “The first thing you have to look at is - do you understand it?” 24:15 Finding the Net Promoter score for Innovation Companies. 28:40 “In Healthcare today the word is ‘Collaboration'.”

See acast.com/privacy for privacy and opt-out information.